Short Bowel Syndrome: Next Step When Comprehensive Medical Management Fails to Achieve Enteral Independence
Not all patients with short bowel syndrome reach enteral independence through optimized dietary and medical management alone. When the goals of the initial treatment line — particularly weaning from parenteral nutrition — remain unmet, a structured escalation is indicated.
When the Previous Treatment Line Did Not Reach Its Goals
Comprehensive medical/nutritional management was applied — including parenteral nutrition (PN) support adjusted to fluid, electrolyte, and nutritional needs; oral rehydration solution; a hyperphagic diet with increased meal frequency; antisecretory therapy; antidiarrheal therapy; octreotide for high-output stool losses; and transdermal clonidine — targeting:
- Adequate hydration with urine output greater than 1 L/day and urinary sodium greater than 20 mEq/L
- Reduction in stool or ostomy output
- Weight maintenance or gain
- Weaning from parenteral nutrition
When these targets — especially PN weaning and enteral independence — are not achieved, this protocol defines the next management step.
Next-Line Treatment Approach (Partial — Full Protocol Below)
For patients who remain unable to achieve enteral independence despite the above measures, the protocol involves a targeted pharmacological intervention that acts on intestinal absorptive function to enable progressive PN weaning — alongside surgical options in selected cases. The complete regimen, eligibility criteria, and structured algorithm are in the full protocol.
Clinical Goals
Improved intestinal absorptive function with progressive weaning from parenteral nutrition, with the primary endpoint of achieving enteral autonomy.
References
DOI: 10.1016/j.cgh.2022.05.032
- The very short half-life of native GLP-2 has been extended to allow daily subcutaneous injection in the recombinant molecule, teduglutide (Gattex; Takeda Pharmaceuticals, Tokyo, Japan).
- Teduglutide can improve intestinal absorptive function and allow PN weaning in patients with SBS-IF, even allowing some patients to achieve enteral autonomy.
- The choice of operation is mainly between the longitudinal intestinal lengthening and tapering (LILT) operation described by Bianchi and the serial transverse enteroplasty (STEP) operation described by Kim et al.
- In patients with SBS, restoration of intestinal continuity and recruitment of any available distal bowel should be accomplished as soon as safely possible to improve bowel function and reduce the risk of or decrease PN dependency.
View source ↗